製品名:5-(piperazin-1-yl)pyridin-2-amine

IUPAC Name:5-(piperazin-1-yl)pyridin-2-amine

CAS番号:1082876-26-3
分子式:C9H14N4
純度:95%+
カタログ番号:CM168972
分子量:178.24

包装単位 有効在庫 価格(USD) 数量
CM168972-50mg in stock ũũ
CM168972-100mg in stock ƥȐũ
CM168972-250mg in stock ƥȺŵ
CM168972-1g in stock ȐŵȺ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:1082876-26-3
分子式:C9H14N4
融点:-
SMILESコード:NC1=NC=C(N2CCNCC2)C=C1
密度:
カタログ番号:CM168972
分子量:178.24
沸点:
MDL番号:MFCD11604842
保管方法:Store at 2-8°C.

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Ribociclib
FDA has approved Novartis Kisqali(ribociclib) to reduce risk of recurrence in people with hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-) early breast cancer (EBC).
Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Beyond today’s FDA approval of Kisqali for EBC patients in the US, regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China.